Development of Non-Invasive Biosensor Devices for the Detection of Bladder Cancer in Urine

Clinical Oncology and Research ◽

10.31487/j.cor.2020.06.11 ◽

2020 ◽

pp. 1-4

Author(s):

Sungyong Jung ◽

Hyusim Park ◽

Jayoung Kim ◽

Sungyong Jung

Keyword(s):

United States ◽

Bladder Cancer ◽

Short Review ◽

The United States ◽

Review Article ◽

Current Status ◽

Device Development ◽

Non Invasive ◽

Common Cancer

Bladder cancer (BC) is the fourth most common malignant tumor in the United States. It is the second most common cancer of the urinary system, accounting for 7% of all new cancer cases. It is also the fifth deadliest cancer, accounting for 4% of all cancer-related deaths in the United States. Our efforts to reduce costs of BC diagnosis and improve patients’ quality of life by avoiding unnecessary invasive diagnostic tests resulted in findings of promising urinary biomarkers for the detection of BC. This short review article aims to provide the current status of non-invasive biosensor device development for detection of BC, in particular, in patients’ urine samples.

Download Full-text

United States Environmental Protection Agency National Radon Proficiency Programmes

Radiation Protection Dosimetry ◽

10.1093/oxfordjournals.rpd.a082470 ◽

1994 ◽

Vol 56 (1-4) ◽

pp. 275-280

Author(s):

P.P. Jalbert ◽

G.L. Salmon ◽

S. De Scisciolo (INVITED)

Keyword(s):

United States ◽

Environmental Protection ◽

Environmental Protection Agency ◽

Technical Assistance ◽

The United States ◽

Current Status ◽

Radon Measurement ◽

The Public ◽

The Us

Abstract The US Environmental Protection Agency's voluntary National Radon Proficiency Programmes: Radon Measurement, and Reduction Proficiency are described, including their history and development, current status and future directions. The Radon Measurement Proficiency (RMP) and Radon Contractor Proficiency (RCP) programmes are fundamental to the Agency's programme to reduce the health risk associated with exposure to elevated radon levels in indoor air. Originally developed to provide technical assistance to States, the proficiency programmes now offer US consumers assurance of the quality of their radon measurements and reduction jobs. In other words, the proficiency programmes provide a means to consumers for deciding from which organisations or individuals to purchase radon services. This is especially important in the United States where most radon services are acquired through private enterprises rather than through the public sector. The Agency encourages the public to purchase radon measurement and reduction services only from organisations or individuals that have met the requirements of EPA's proficiency programmes. An increasing number of States require an EPA proficiency listing for their radon registration, licensing, and certification programmes. EPA estimates that about 85% of US companies offering radon services are participating in its proficiency programmes. Consequently, the Agency believes that the development and growth of quality radon services has kept pace with consumer demand. The United States markeplace for residential radon measurement and mitigation services has been dynamic since its inception in the mid-1980s. The fluidity of the market is likely to continue, with some significant changes appearing imminent. The US Congress is now considering legislation that would require participation in the Agency's radon proficiency programmes. In addition, this legislation contains provisions that would encourage consumer testing. Increased testing, coupled with a mandatory national proficiency programme, is likely to result in an increase in the quality of radon services available to the US public.

Download Full-text

Bladder Cancer

Journal of the National Comprehensive Cancer Network ◽

10.6004/jnccn.2006.0083 ◽

2006 ◽

Vol 4 (10) ◽

pp. 984 ◽

Cited By ~ 18

Author(s):

_ _

Keyword(s):

United States ◽

Bladder Cancer ◽

Management Strategies ◽

Urinary Bladder Cancer ◽

The United States ◽

Therapeutic Goals ◽

Metastatic Lesions ◽

Common Cancer ◽

Age Of Diagnosis ◽

Recent Version

An estimated 61,420 new cases of urinary bladder cancer will be diagnosed in the United States in 2006, making it the fourth most common cancer in men and the ninth most common neoplasm in women. Because the median age of diagnosis is 65 years, medical comorbidities are a frequent consideration. The clinical spectrum of bladder cancer can be divided into 3 categories: noninvasive tumors, invasive lesions, and metastatic lesions. These categories differ in prognosis, management, and therapeutic goals, and these guidelines discuss management strategies to achieve the best possible outcomes. For the most recent version of the guidelines, please visit NCCN.org

Download Full-text

Morphologic characteristics of the urothelial bladder tumors

Acta chirurgica iugoslavica ◽

10.2298/aci0704101r ◽

2007 ◽

Vol 54 (4) ◽

pp. 101-104

Author(s):

R. Radosavljevic ◽

J. Hadzi-Djokic ◽

M. Acimovic ◽

T. Pejcic ◽

C. Tulic ◽

...

Keyword(s):

United States ◽

Risk Factors ◽

Bladder Cancer ◽

The United States ◽

Premalignant Lesions ◽

Bladder Tumors ◽

Common Cancer ◽

Morphologic Characteristics ◽

Urothelial Bladder ◽

Develop Bladder Cancer

Cancer of the urinary bladder is the fourth most common cancer in men and the ninth in women. Approximately 67.000 people (50.000 males and 17. 000 females) develop bladder cancer each year in the United States, and 13.750 individuals (9.630 males and 4.120 females) are expected to die from it. In the showing of the morphologic characteristics of the tumors, authors underlining the increasing of the incidence, pathogenesis, premalignant lesions and the risk factors of disease.

Download Full-text